Back to the feed

Home › US bills › H.R. 3029

United States

H.R. 3029

To amend the Research and Development, Competition, and Innovation Act to support nucleic acid screening, and for other purposes.

Commerce, Science, and Transportation Committee, Science, Space, and Technology Committee · Rep. Andrea Salinas (D-OR)

Official summary (Congressional Research Service, Introduced in House): Nucleic Acid Standards for Biosecurity Act

This bill explicitly requires the National Institute of Standards and Technology (NIST) to support the development of best practices and technical standards for nucleic acid synthesis.

Nucleic acids, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), carry genetic information within cells. Nucleic acid synthesis is the process of designing and creating custom nucleic acids; it is used in the development of medications and agricultural products. However, this technology also poses a risk of misuse (e.g., the intentional or unintentional creation of dangerous biological agents).

The bill requires NIST to carry out measurement research to support the development and improvement of biosecurity best practices and technical standards related to nucleic acid synthesis. This effort must address specified topics including nucleic acid synthesis screening, operational security, and conformity assessment. (A 2023 executive order titled Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence directed NIST to develop and refine similar specifications and best practices for use by synthetic nucleic acid providers. NIST's work on this topic is ongoing.)

In carrying out this effort, NIST must convene stakeholders to develop and periodically update consensus priorities and best practices for synthetic nucleic acid screening mechanisms. Within a specified period, NIST must submit a summary of the stakeholder group’s findings to Congress.

NIST must also take steps to advance risk management best practices and technical standards for engineering biology and biomanufacturing, including with respect to risks associated with the use of artificial intelligence.

Passed House with amendment (voice vote) 20 July 2026

Record as of 21 July 2026 — the most recent action in the official record. Status can lag; each step below carries its own date.

  1. 21 July 2026 Received in the Senate and Read twice and referred to the Committee on Commerce, Science, and Transportation.
  2. 20 July 2026 Passed House with amendment (voice vote)
  3. 4 more actions
    1. 20 July 2026 Motion to reconsider laid on the table Agreed to without objection.
    2. 20 July 2026 DEBATE - The House proceeded with forty minutes of debate on H.R. 3029.
    3. 20 July 2026 Considered under suspension of the rules. (consideration: CR H4666-4667)
    4. 20 July 2026 Mr. Babin moved to suspend the rules and pass the bill, as amended.
  4. 16 July 2026 Reported by committee
  5. 16 July 2026 Placed on calendar (House)
  6. 2 more actions
    1. 29 April 2025 Ordered to be Reported by Voice Vote.
    2. 29 April 2025 Committee Consideration and Mark-up Session Held
  7. 28 April 2025 Referred to committee
  8. 28 April 2025 Introduced in House
This path starts where the bill does — its first action in the official record. Routine procedural steps sit in the “more actions” rows above rather than on the main line.